My research focuses on the regulation of prostate-specific antigen (PSA) promoter in the hormonal-refractory prostate cancer and the development of gene therapy strategy for prostate cancer and osteosarcoma. Adenocarcinoma of prostate has become a significant health problem and is one of the leading cancers in the industrialized Western world. It is the most commonly diagnosed cancer and the second leading cause of death from cancer among males in the United States. In local advanced diseases and/or metastatic prostate cancer, androgen withdrawal is able to delay the progression of the disease; but, inevitably, the neoplasm will develop to a hormone-resistant stage, androgen-independent (AI), and will finally lead to death.
